stockrow
Monday 9 November 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLCBasic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- +64.7%
- Free cash flow
- +44.3%
Quarter to June 2026, against a year earlier
0.83
0.03
−3.49%
Follow BGLC
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.51 | 0.97 | 0.99 | 1.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.16) | (35.02) | 7.63 | (7.94) | |
P/B ratio |
0.61 | 0.64 | 0.85 | 1.44 | |
Price to Tangible BV |
0.61 | 0.64 | 0.85 | 1.44 | |
EV/Sales |
0.40 | 0.24 | 0.46 | 0.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.46) | (1.08) | (1.85) | (2.73) | |
EV/FCF |
(1.45) | (1.05) | (1.81) | (2.69) | |
Quick Ratio |
4.56 | 5.27 | 9.00 | 6.81 | |
Current Ratio |
6.08 | 6.52 | 10.46 | 8.30 | |
Net Debt/EBITDA |
15.98 | 8.17 | 4.12 | 4.53 | |
Debt/Assets |
0.52% | 0.52% | 0.00% | 0.00% | |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.34 | 0.57 | 0.75 | 1.02 | |
Operating CF/Net income |
1.47 | 0.27 | (0.93) | 1.75 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.02) | (0.13) | |
Research and Development Expense of Revenue |
17.98% | 63.60% | 2.29% | 0.59% | |
Selling, General and Administrative Expense of Revenue |
438.98% | 1,668.42% | 209.07% | 39.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.85 | 0.82 | 0.66 | 0.49 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.62%) | (69.16%) | (40.43%) | (23.23%) | |
Free Cash Flow Yield |
(18.11%) | (23.01%) | (25.57%) | (26.66%) | |
Revenue per Share |
0.03 | 0.01 | 0.26 | 1.42 | |
Operating CF per Share |
(0.17) | (0.06) | 0.52 | (0.69) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.06) | 0.52 | (0.69) | |
Cash per Share |
1.46 | 1.64 | 2.18 | 1.61 | |
Shareholders Equity per Share |
3.22 | 3.35 | 4.64 | 3.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.22 | 3.35 | 4.64 | 3.79 | |
Free Cash Flow |
(0.42) | (0.15) | 0.96 | (1.24) | |
Working Capital |
4.13 | 4.40 | 4.93 | 4.95 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
4.00 | 4.25 | 4.81 | 4.82 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.15 | 1.00 | 1.16 | 1.62 | |
Average Payables |
0.60 | 0.75 | 0.52 | — | |
Average Inventory |
0.93 | 0.92 | 1.03 | 1.20 | |
Average Assets |
9.07 | 9.26 | 9.84 | 9.31 | |
Average Common Equity |
7.65 | 7.93 | 8.47 | 8.10 |
Columns are period end dates · fundamentals updated 26 Oct 2026